- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02256826
Study of Pharmacokinetic Interaction Between Kaletra® (LPV/r) and BILR 355 BS Plus Ritonavir in Healthy Subjects
October 2, 2014 updated by: Boehringer Ingelheim
Study of Pharmacokinetic Interaction Between Kaletra® (LPV/r) and BILR 355 BS Plus Ritonavir
To determine the pharmacokinetic effect of BILR 355 BS on Kaletra® and of Kaletra® on BILR 355 BS
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
34
Phase
- Phase 1
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 59 years (Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Males or females who meet the inclusion/exclusion criteria; females must not be pregnant or nursing, and agree to use a double-barrier method of birth control (condoms or diaphragm plus spermicide) throughout the trial (alone or in addition to other methods of birth control such as oral contraceptives)
- Age ≥18 and <60 years
- BMI ≥18.5 and BMI ≤29.9 kg/m2
- Ability to give signed and dated written informed consent prior to admission to the study in accordance with Good Clinical Practice (GCP) and the local regulations
Exclusion Criteria:
- Current (symptomatic within the last 30 days) and medically relevant gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders
- Surgery of gastrointestinal tract (except appendectomy)
- Currently active (symptomatic within the last 30 days) diseases of the central nervous system (such as epilepsy) or psychiatric disorders or neurological disorders
- History of relevant orthostatic hypotension, fainting spells or blackouts
- History of allergy/hypersensitivity (including drug allergy) which is deemed relevant to the trial as judged by the investigator
- Intake of drugs with a long half-life (>24 hours) within one month prior to administration of study drug or during the trial (review with clinical monitor if questionable)
- Use of drugs within 10 days prior to administration or during the trial, which might reasonably influence the results of the trial based on the knowledge at the time of protocol preparation (review with clinical monitor if questionable)
- Participation in another trial with an investigational drug within one month prior to administration or during the trial
- Current smoker
- Alcohol (more than 60 g/day) or drug abuse (positive urine test for illicit prescription or non-prescription drugs or drugs of abuse)
- Recent blood donation (more than 100 mL within 4 weeks prior to administration or during the trial)
- Excessive physical activities (within 1 week prior to study drug administration or during the trial)
- Any laboratory value outside the normal reference range that is of clinical relevance at screening, according to the judgment of the investigator
- Inability to comply with dietary regimen required by the protocol
- Chronic or relevant acute infections
- Infected with hepatitis B or hepatitis C viruses (defined as either being hepatitis B surface antigen, or hepatitis C antibody positive)
- HIV-1 infected as defined by a positive HIV ELISA test
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Group A
|
NORVIR®
(lopinavir (LPV) and ritonavir (RTV))
|
Experimental: Group B
|
NORVIR®
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Area under the concentration-time curve of the analyte in plasma over one dosing interval (12 hours) at steady state (AUC0-12h,ss)
Time Frame: Up to 12 h after the last drug administration of BILR 355
|
Up to 12 h after the last drug administration of BILR 355
|
Maximum measured concentration of the analyte in plasma at steady state over a dosing interval τ (Cmax,ss)
Time Frame: Up to 96 h after the last drug administration of BILR 355
|
Up to 96 h after the last drug administration of BILR 355
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Apparent clearance of the analyte in plasma following extravascular administration at steady state (CL/F,ss)
Time Frame: Up to 96 h after the last drug administration of BILR 355
|
Up to 96 h after the last drug administration of BILR 355
|
Time from dosing to the maximum concentration of the analyte in plasma at steady state (tmax,ss)
Time Frame: Up to 96 h after the last drug administration of BILR 355
|
Up to 96 h after the last drug administration of BILR 355
|
Terminal half-life of the analyte in plasma at steady state (t1/2,ss)
Time Frame: Up to 96 h after the last drug administration of BILR 355
|
Up to 96 h after the last drug administration of BILR 355
|
Apparent volume of distribution during the terminal phase λz at steady state following an extravascular dose (Vz/F,ss)
Time Frame: Up to 96 h after the last drug administration of BILR 355
|
Up to 96 h after the last drug administration of BILR 355
|
Area under the plasma concentration time curve (0-12 hours) (AUC0-12h) for RTV
Time Frame: Up to 12 h after RTV administration
|
Up to 12 h after RTV administration
|
Maximum measured concentration of the analyte in plasma at steady state (Cmax,ss) for RTV
Time Frame: Up to 96 h after the last drug administration of BILR 355
|
Up to 96 h after the last drug administration of BILR 355
|
Measured concentration of the analyte in plasma 12 hours post last dose at steady state (Cp12h,ss)
Time Frame: Up to 12 h after the last drug administration of BILR 355
|
Up to 12 h after the last drug administration of BILR 355
|
Number of participants with Adverse Events
Time Frame: Up to day 35 after first drug administration
|
Up to day 35 after first drug administration
|
Number of participants with abnormal changes in clinical laboratory parameters
Time Frame: Up to day 35 after first drug administration
|
Up to day 35 after first drug administration
|
Number of participants with abnormal findings in physical examination
Time Frame: Up to day 35 after first drug administration
|
Up to day 35 after first drug administration
|
Number of participants with clinically significant changes in vital signs
Time Frame: Up to day 35 after first drug administration
|
Up to day 35 after first drug administration
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Helpful Links
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
April 1, 2005
Primary Completion (Actual)
June 1, 2005
Study Registration Dates
First Submitted
October 2, 2014
First Submitted That Met QC Criteria
October 2, 2014
First Posted (Estimate)
October 6, 2014
Study Record Updates
Last Update Posted (Estimate)
October 6, 2014
Last Update Submitted That Met QC Criteria
October 2, 2014
Last Verified
October 1, 2014
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 1188.8
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy
-
Prevent Age Resort "Pervaya Liniya"RecruitingHealthy Aging | Healthy Diet | Healthy LifestyleRussian Federation
-
Maastricht University Medical CenterCompletedHealthy Volunteers | Healthy Subjects | Healthy AdultsNetherlands
-
Yale UniversityNot yet recruitingHealth-related Benefits of Introducing Table Olives Into the Diet of Young Adults: Olives For HealthHealthy Diet | Healthy Lifestyle | Healthy Nutrition | CholesterolUnited States
-
Hasselt UniversityRecruitingHealthy | Healthy AgingBelgium
-
Galera Therapeutics, Inc.Syneos HealthCompleted
-
Galera Therapeutics, Inc.Syneos HealthCompletedHealthy | Healthy VolunteersAustralia
-
University of PennsylvaniaActive, not recruitingHealthy | Healthy AgingUnited States
-
Chalmers University of TechnologyGöteborg UniversityCompletedHealthy | Nutrition, HealthySweden
-
University of ManitobaNot yet recruitingHealthy | Healthy Diet
Clinical Trials on BILR 355 BS
-
Boehringer IngelheimCompleted
-
Boehringer IngelheimCompleted
-
Boehringer IngelheimCompleted
-
Boehringer IngelheimTerminated
-
Boehringer IngelheimCompleted
-
Boehringer IngelheimCompleted
-
Bio Products LaboratoryCompletedCommon Variable Immunodeficiency | Wiskott-Aldrich Syndrome | X-linked Agammaglobulinemia | Primary Immune Deficiency Disorders | Hyper-IgM SyndromeUnited States, Chile, Israel
-
Boehringer IngelheimCompleted
-
Boehringer IngelheimCompleted